Skip to Main Content (Press Enter)
×
Home
Corsi
Insegnamenti
Professioni
Persone
Pubblicazioni
Strutture
Terza Missione
Attività
Competenze
IT
EN
☰
UNI-FIND
|
UNI-FIND
unimore.it
IT
EN
×
Home
Corsi
Insegnamenti
Professioni
Persone
Pubblicazioni
Strutture
Terza Missione
Attività
Competenze
☰
Pubblicazioni
THE LANCET RESPIRATORY MEDICINE
Rivista
Codice:
E222728
ISSN:
2213-2600
Dati Generali
Dati Generali
Pubblicazioni (23)
Pulisci
Ordina Pubblicazioni:
ascendente
decrescente
A new chance to treat rheumatoid arthritis lung fibrosis?
Articolo
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
Articolo
Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial
Articolo
Benralizumab: for asthma, not yet for COPD
Articolo
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial
Articolo
Blood eosinophils for the management of COPD patients?
Articolo
Breakthroughs in internal and respiratory medicine
Articolo
Caution advised regarding lung recruitment before surfactant – Authors’ reply
Articolo
Correction to Lancet Respir Med 2023; 11: 3–4 (The Lancet Respiratory Medicine (2023) 11(1) (3–4), (S2213260022003563), (10.1016/S2213-2600(22)00356-3))
Articolo
Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial
Articolo
Eosinophilia in asthma: the easy way is not always the best
Articolo
Inhaled steroids in COPD: when should they be used?
Articolo
Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial
Articolo
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Articolo
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
Articolo
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
Articolo
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
Articolo
Rare lung disease and orphan drug development
Articolo
Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial
Articolo
Rituximab for connective tissue disease-associated interstitial lung disease
Articolo
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
Articolo
Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies
Articolo
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
Articolo
No Results Found
«
‹
{pageNumber}
›
»
{startItem} - {endItem} di {itemsNumber}
5 per pagina
10 per pagina
30 per pagina
vedi tutti
